



November 9, 2021

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001.  
**Ref:- Scrip Code:- 500126**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai - 400051  
**Ref:- Symbol:- PGHL**

Dear Sir / Madam,

**Sub:- Unaudited Financial Results for the quarter ended September 30, 2021**

We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended September 30, 2021 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended September 30, 2021;
- b. Press Release; and
- c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended September 30, 2021 furnished by Statutory Auditors of the Company

Kindly take the same on record and oblige.

Thanking you,

Yours faithfully,

***For Procter & Gamble Health Limited***

ZEAL JAYESH SHAH  
Digitally signed by  
ZEAL JAYESH SHAH  
Date: 2021.11.09  
17:44:59 +05'30'

***Zeal Shah***

***Company Secretary***

**Procter & Gamble Health Limited**

CIN: L99999MH1967PLC013726

Registered Office: Godrej One, 8<sup>th</sup> Floor,

Pirojshanagar, Eastern Express Highway, Vikhroli East,

Mumbai 400 079 | Tel: (91-22) 6866 9000

[www.pghealthindia.com](http://www.pghealthindia.com)

**PROCTER & GAMBLE HEALTH LIMITED**

Regd. Office: Godrej One, 8th Floor, Eastern Express Highway, Pirojshanagar, Vikhroli (East), Mumbai : 400 079.

Highly Restricted

CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 SEPTEMBER 2021**

(₹ in lakhs)

Sr. No.	Particulars	(1)	(2)	(3)	(4)
		Three months ended 30th September 2021 Unaudited	Preceding Three months ended 30th June 2021 Audited [Refer note 4]	Corresponding Three months ended 30th September 2020 Unaudited	Year ended 30th June 2021 Audited
1.	<b>Revenue from Operations</b>	27,280.0	28,539.0	26,397.0	1,00,873.0
2.	<b>Other Income</b>	304.0	242.0	672.0	1,810.0
3.	<b>Total income (1+2)</b>	27,584.0	28,781.0	27,069.0	1,02,683.0
4.	<b>Expenses</b>				
	a) Cost of materials consumed	9,299.0	7,190.0	9,305.0	28,912.0
	b) Purchases of stock-in-trade	651.0	814.0	516.0	2,116.0
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	(1,697.0)	946.0	(325.0)	454.0
	d) Employee benefits expense	3,951.0	4,388.0	3,814.0	15,047.0
	e) Depreciation and amortisation expense	690.0	716.0	736.0	3,004.0
	f) Finance Costs	14.0	17.0	24.0	80.0
	g) Other expenses	7,269.0	10,357.0	5,277.0	29,742.0
	<b>Total expenses (4)</b>	20,177.0	24,428.0	19,347.0	79,355.0
5.	<b>Profit before exceptional items and tax (3-4)</b>	7,407.0	4,353.0	7,722.0	23,328.0
6.	Less: Exceptional items	-	-	-	-
7.	<b>Profit before tax (5-6)</b>	7,407.0	4,353.0	7,722.0	23,328.0
8.	<b>Tax expenses</b>				
	Current Tax	1,930	1,322.0	2,034.0	6,360.0
	Deferred Tax	(60)	(377.0)	(93.0)	(490.0)
	Tax for earlier years	-	19.0	(145.0)	(222.0)
9.	<b>Net Profit for the period/ year (7-8)</b>	5,537.0	3,389.0	5,926.0	17,680.0
10.	<b>Other Comprehensive Income</b>				
	Items that will not be reclassified to profit or loss				
	i. Re-measurement gains/(losses) on defined benefit plans	(22.0)	551.0	(27.0)	56.0
	ii. Income tax effect	6.0	(139.0)	7.0	(14.0)
	<b>Total Other Comprehensive Income, net of tax</b>	(16.0)	412.0	(20.0)	42.0
11.	<b>Total Comprehensive Income for the period/year (9+10)</b>	5,521.0	3,801.0	5,906.0	17,722.0
12.	Paid-up equity share capital (Face Value Rs 10/- each)	1,660.0	1,660.0	1,660.0	1,660.0
13.	Other equity excluding Revaluation reserve as per Balance sheet	-	-	-	68,711.0
14.	<b>Earnings per equity share (of Rs 10/- each) *(not annualised)</b>				
	(a) Basic and Diluted (in Rs.)	* 33.4	* 20.4	* 35.7	* 106.5

**Notes:**

- The above financial results for the quarter ended September 30, 2021 have been reviewed by the Audit Committee, and approved by the Board of Directors of the Company at their Meeting held on November 9, 2021 and have been subject to a limited review by the Statutory Auditors of the Company.
- Results for all above period have been prepared in accordance with Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.
- The Company operates under only one segment i.e. Pharmaceuticals. Accordingly, no separate segment information has been provided.
- Previous period figures have been regrouped/ reclassified wherever necessary. The figures for the preceding three months ended 30th June 2021 are balancing figures between the audited figures in respect of full financial year ended 30th June 2021 and year to date figures upto the third quarter of that financial year.

Place : Mumbai

Date : 9 November 2021

Please visit us at our website [www.pghealthindia.com](http://www.pghealthindia.com)

For Procter & Gamble Health Limited

MILIND VASANT  
THATTE

Milind Thatte  
Managing Director  
DIN: 08092990

Digitally signed by  
MILIND VASANT THATTE  
Date: 2021.11.09  
17:53:59 +05'30'



## Procter & Gamble Health Limited Announces First Quarter results

Sales of ₹ 267.8 Crores and PAT of ₹ 55.4 Crores for quarter ended September 30, 2021

Sales for the quarter up by 4%

**Mumbai, Nov 09, 2021:** Procter & Gamble Health Limited announced today its financial results for the quarter ended September 30, 2021. The company has recorded a strong performance with sales of ₹ 267.8 crores, up 4% vs a year ago. The Profit After Tax (PAT) was ₹ 55.4 crores against ₹ 59.3 crores a year ago.

**Milind Thatte, Managing Director, Procter & Gamble Health Limited said,** *“We delivered a strong performance in our first quarter of fiscal 2022 focused on executing our strategies of offering superior brands, driving productivity, increasing reach, and improving awareness. With the country gradually easing restrictions further due to improved vaccination coverage, we will continue our strategy to leverage technology and deliver constructive disruption to better serve our consumers and customers who count on our brands and the benefits they provide.”*

*While the pandemic remains, so does our commitment to step up as a #forceforgood and a #forceforgrowth guided by our three core principles; protecting the health and safety of our employees and partners, ensuring uninterrupted supplies of our quality and affordable products, and supporting communities and relief efforts through our flagship CSR program ‘SEHAT’ (meaning Health),”* he further added.

### About Procter & Gamble Health Limited:

Procter & Gamble Health Limited is one of India’s largest VMS Companies manufacturing and marketing over-the-counter vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit [www.pghealthindia.com](http://www.pghealthindia.com) for the latest news and information about Procter & Gamble Health Limited and its brands.

### About Procter & Gamble:

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide.

### CONTACTS

#### Media Contacts - Procter & Gamble Health Limited:

- Ruchita Mehra | [mehra.r@pg.com](mailto:mehra.r@pg.com)
- Paromita Kundu | [kundu.p.1@pg.com](mailto:kundu.p.1@pg.com)

#### Investor Relations Contact:

- Flavia Machado | [machado.f.1@pg.com](mailto:machado.f.1@pg.com)

### Registered Office :

**Procter & Gamble Health Limited**  
CIN: L99999MH1967PLC013726  
Godrej One, 8<sup>th</sup> Floor, Pirojshanagar,  
Eastern Express Highway, Vikhroli East,  
Mumbai 400 079 | Tel: (91-22) 6866 9000

### Site Address:

**Procter & Gamble Health Limited**  
CIN: L99999MH1967PLC013726  
Usgaon, Ponda Taluka,  
Goa 403 407 | Tel: (91-832) 2347105  
[www.pghealthindia.com](http://www.pghealthindia.com)

**Independent Auditor's Review Report on quarterly Unaudited Financial Results of Procter & Gamble Health Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015**

**To the Board of Directors**

**Procter & Gamble Health Limited**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Procter & Gamble Health Limited** ("the Company") for the quarter ended September 30, 2021 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as



# HARIBHAKTI & CO. LLP

Chartered Accountants

amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W/W100048



---

Hemant J. Bhatt

Partner

Membership No.: 036834

UDIN: 21036834AAAACT6555

Place: Mumbai

Date: November 09, 2021